circadian rhythm raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-19 and is reviewed periodically as new material appears.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Mercenaries and multinational corporations such as Chiquita Brands International are some of the international actors that have contributed to the violence of the conflict. Beginning in the mid-1970s Colombian drug cartels became major producers, processors and exporters of illegal drugs, primarily marijuana and cocaine. On 4 July 1991, a new Constitution was promulgated. The changes generated by the new constitution are viewed as positive by Colombian society.
== Medical application == S. helianthus shows a variety of promising applications in the medical field due to its toxin-producing capability. ShK-186, a peptide inhibitor, is a toxin that has been previously implemented in clinical trials for its potential treatment of autoimmune diseases. It has been further developed into an “investigational drug”, known as Dalazatide, in which it targets the disease-causing cells corresponding to ailments including type 1 diabetes, lupus erythematosus and multiple sclerosis. The aforementioned cytolysins, St I and St II, have also shown pharmacological potential in studies with guinea pig models, with direct implications on neural and cardiac activity. Due to its capability of protease inhibition, ShPI-1 is another toxin with medical potential. This toxin is a “non-specific inhibitor” and provides a variant with “increased biomedical potential” for its inhibition properties. Though many of these toxins require further research, S. helianthus serves great potential in biomedical applications for toxin production.
Phillips and Connelly had an agreement that distribution of MET-Rx would be controlled, and that they would not sell it to retail outlets in order to keep supply low during the period of high demand created by the advertisements in Muscle Media 2000. Connelly however, had other ideas and began selling it to mainstream distributors and department stores. Phillips believed this move lessened its appeal to bodybuilders, and destroyed the "mystique" of the product. The two parted ways, and as part of the settlement, Phillips was legally bound not to mention the name of MET-Rx in his magazines (thereafter he would refer to it as "the leading brand"). But by then Phillips had his eye on another venture that would eclipse MET-Rx altogether – EAS.
1993/2924) Social Security (Contributions) Amendment (No. 7) Regulations 1993 (S.I. 1993/2925) Dundee Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2926) Falkirk and District Royal Infirmary National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2927) Hairmyres and Stonehouse Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2928) Law Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2929) Perth and Kinross Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2930) East and Midlothian National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2931) Royal Infirmary of Edinburgh National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2932) Western General Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2933) Dumfries and Galloway Acute and Maternity Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2934) Glasgow Community and Mental Health Services National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2935) Edinburgh Sick Children's National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2936) Fife Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2937) Edinburgh Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2938) Petroleum Revenue Tax (Nomination Scheme for Disposals and Appropriations) (Amendment) Regulations 1993 (S.I.
==== Fibrosis ==== In accordance with the known expression of αvβ6-integrin in early lung fibrosis, 68Ga-Trivehexin was used for PET/CT imaging of idiopathic pulmonary fibrosis (IPF). In explorative studies, 68Ga-Trivehexin could generate an IPF-specific PET signal while the same tissue areas were PET-negative using the standard metabolic PET tracer 18F-FDG. 68Ga-Trivehexin PET scans displayed an uptake of SUVmax = 5.53 in fibrotic lung areas and thus enabled clear differentiation of fibrotic from non-fibrotic lung tissue.
Sources: en.wikipedia.org
== Analysis == Quincy Institute's political scientist Annelle Sheline has argued that Trump's plan for Gaza would not only constitute ethnic cleansing, but would also destabilize the Middle East, since the displacement of Palestinians into Jordan would provoke a period of social upheaval that could topple the Jordanian monarchy and create an entirely new state in the region. She argued that if such an event were to take place, the Jordanian Muslim Brotherhood could seize control of the country. This view has been supported by Paul Piller (fellow at the Quincy Institute) who argued that the displacement of Palestinians into Jordan would effectively end the Jordanian-Israeli peace agreement of 1994 and risk the overthrow of the Jordanian monarchy. Oraib Rantawi, head of the Amman Al Quds Center for Political Studies, said the plan would affect Jordan's demography, identity, and security. Egyptian officials warned that the inflow of hundreds of thousands of Hamas militants into the Sinai border resulting from the plan would destabilize the region and put Egypt's peace agreement with Israel in jeopardy. Also at the Quincy Institute, Rabwan Ahari has argued that Trump's proposal signals a clear and substantial departure from America having "even the pretense of supporting a two-state solution." They further argued that this plan amounted to a statement that Palestinian displacement was the goal of US policy surrounding the region.
Examples of iron-containing proteins in higher organisms include hemoglobin, cytochrome (see high-valent iron), and catalase. The average adult human contains about 0.005% body weight of iron, or about four grams, of which three quarters is in hemoglobin—a level that remains constant despite only about one milligram of iron being absorbed each day, because the human body recycles its hemoglobin for the iron content. Microbial growth may be assisted by oxidation of iron(II) or by reduction of iron(III).
== External links == Attorney General Ellison files lawsuit against COVID-19 testing sites, lab for deceiving consumers, Minnesota Attorney General, January 19, 2022 Complaint in State of Minnesota, by its Attorney General, Keith Ellison v. Center for COVID Control, LLC and Doctors Clinical Laboratory, Inc., filed in Hennepin County District Court on January 19, 2022, file # 27-CV-22-731
== Doping scandals == Doping in sport Ben Johnson's positive test for steroids after his 1988 Olympic victory in the 100 metres The Festina affair – a series of doping investigations and scandals surrounding the 1998 Tour de France, initially focusing on the Festina cycling team, but quickly spreading to several other teams. The Mitchell Report – 88 current and former Major League Baseball (MLB) players were alleged to have used steroids or other performance-enhancing drugs. The conviction of Barry Bonds (2011) – later overturned on obstruction of justice charges relating to the BALCO investigation Operación Puerto (2006) – a Spanish investigation into a doping scheme allegedly involving many top cyclists, including several potential contenders in the 2006 Tour de France. Floyd Landis doping case (2006) – Floyd Landis, initially the winner of the 2006 Tour de France, tested positive for synthetic testosterone and was stripped of his title. Doping at the 2007 Tour de France – the 2007 Tour de France was rocked by a series of doping scandals. Two riders, including pre-race favorite Alexander Vinokourov, were disqualified for doping offenses. Both teams involved pulled out of the Tour. A third rider, who had abandoned the Tour after a crash, was revealed to have tested positive for testosterone before the Tour. The race leader, Michael Rasmussen, was removed from the Tour by his team with four stages left amid questions surrounding his possible involvement in doping.
=== Clothing === A process to apply zinc pyrithione to cotton with washable results was patented in the United States in 1984. Zinc pyrithione is used to prevent microbe growth in polyester. Textiles with applied zinc pyrithione protect against odor-causing microorganisms. Export of antimicrobial textiles reached US$497.4 million in 2015.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.